Minnesota is currently home to 2064 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Use of Midodrine in Septic Shock Patients
NCT06319248
Recruiting
This study is being done to determine if early administration of Midodrine can improve outcomes by maintaining a higher mean blood pressure off of intravenous medications. Researchers want to see if Midodrine can help people with sepsis need fewer vasopressors, which could mean shorter hospital stays, less time with uncomfortable tubes, and a smoother recovery overall.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: Mayo Clinic Minnesota, Rochester, Minnesota
Conditions: Sepsis, Low Blood Pressure
Register for Updates
Evaluation of Oral Potentially Malignant Disorders (OPMDs) with STRATICYTE™
NCT05853783
Recruiting
The purpose of this study is to validate the ability of the STRATICYTE™ predictive model to predict the transformation of oral potentially malignant disorders (OPMDs) to oral squamous cell carcinoma (OSCC) in a retrospective cohort of patients who received biopsies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: Minnesota Oral and Facial Surgery, Minneapolis, Minnesota
Conditions: Mouth Diseases
Register for Updates
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
NCT04580420
Recruiting
The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.
Gender:
ALL
Ages:
All
Trial Updated:
11/05/2024
Locations: Clinical Trial Site, Rochester, Minnesota
Conditions: End Stage Renal Disease, Primary Hyperoxaluria Type 1
Register for Updates
Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)
NCT04315324
Recruiting
This phase II trial studies how well OBI-3424 works in treating patients with T-cell acute lymphoblastic leukemia that has come back (relapsed) or does not response to treatment (refractory). Drugs used in chemotherapy, such as OBI-3424, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. OBI-3424 may reduce the amount of leukemia in the body.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: Fairview Ridges Hospital, Burnsville, Minnesota
Conditions: Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia
Register for Updates
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
NCT02418442
Recruiting
Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
11/05/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Rheumatic Joint Disease
Register for Updates
Patient and Caregiver Priorities in Neuro-oncology Care
NCT06676306
Recruiting
This study is being done to identify patient and caregiver burdens regarding their experience with diagnosis and treatment of CNS tumors. These results will help doctors find areas where patients and caregivers may need more support.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Malignant Central Nervous System Neoplasm, Metastatic Malignant Neoplasm in the Central Nervous System
Register for Updates
Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity: A Feasibility Study of the Vigilant App (Vigilant-2)
NCT06675643
Recruiting
This study is being done to better understand patient experiences with using a mobile application, known as Vigilant, to monitor symptoms as outpatients and to gather preliminary data on the potential clinical benefit to remote monitoring of adverse events.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Malignant Skin Neoplasm, Melanoma
Register for Updates
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
NCT05863195
Recruiting
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the liver (liver metastases) and cannot be removed by surgery (unresectable). HAI uses a catheter to carry a tumor-killing chemotherapy drug called floxuridine directly into the liver. HAI is already approved by the Food and Drug Administration (FDA) for use in metas... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
Register for Updates
North American Prodromal Synucleinopathy Consortium Stage 2
NCT05826457
Recruiting
This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: REM Sleep Behavior Disorder, Parkinson Disease, Lewy Body Dementia, Dementia With Lewy Bodies, Multiple System Atrophy, REM Sleep Parasomnias
Register for Updates
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171
Recruiting
The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: CentraCare Health, Saint Cloud, Minnesota
Conditions: Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
Register for Updates
Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function
NCT05001269
Recruiting
The aim of this study is to evaluate nedosiran in participants 11 years of age and younger who have Primary Hyperoxaluria with relatively intact renal function.
Gender:
ALL
Ages:
11 years and below
Trial Updated:
11/04/2024
Locations: Clinical Research Site, Rochester, Minnesota
Conditions: Primary Hyperoxaluria, Primary Hyperoxaluria Type 2, Primary Hyperoxaluria Type 1, Primary Hyperoxaluria Type 3
Register for Updates
Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer
NCT04559139
Recruiting
This phase II/III trial compares the effect of adding chemotherapy before and after surgery versus after surgery alone (usual treatment) in treating patients with stage II-III gallbladder cancer. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before surgery may make the tumor smaller; therefore, may reduce the exten... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Sanford Joe Lueken Cancer Center, Bemidji, Minnesota
Conditions: Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8, Stage IIB Gallbladder Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage IIIA Gallbladder Cancer AJCC v8, Stage IIIB Gallbladder Cancer AJCC v8
Register for Updates